NCT05879120: Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma |
|
|
| Withdrawn | 2 | 10 | US | Pembrolizumab, Keytruda, MK-3475, SCH-900475, Exablate MRgFUS + neoadjuvant pembolizumab | M.D. Anderson Cancer Center, InSightec, Merck Sharp & Dohme LLC | Recurrent Glioblastoma | 10/24 | 10/24 | | |
NCT00555399: Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM) |
|
|
| Terminated | 1/2 | 55 | US | Vorinostat, SAHA, Suberoylanilide Hydroxamic Acid, MSK-390, Zolinza, Isotretinoin, cRA, Accutane, 13-cis-Retinoic Acid, Surgical Resection, Temozolomide, Temodar | M.D. Anderson Cancer Center, Merck Sharp & Dohme LLC | Glioblastoma Multiforme, Anaplastic Glioma | 01/20 | 01/20 | | |
NCT03382977: Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects |
|
|
| Recruiting | 1/2 | 98 | US | VBI-1901, Carmustine, BiCNU, Lomustine, Gleostine | VBI Vaccines Inc. | Glioblastoma Multiforme | 07/25 | 08/25 | | |
